How FOXO4-DRI works
An experimental cell-clearing peptide with mouse findings and no established human dose.
Also called: FOXO4 DRI, FOXO4-D-retro-inverso, FOX04-DRI, Proxofim.
Senolytic peptides · Experimental FOXO4-p53 interaction-disrupting peptide · Evidence: Animal studies only.
Some senescent cells use the proteins FOXO4 and p53 to stay alive. This peptide disrupts their contact and can trigger cell death. That mechanism is supported by lab work; its selectivity in people is unknown.
- FOXO4-p53 interaction: Competes for a p53 binding region involved in senescent-cell survival.
- p53-linked cell-death signals: Can move active p53 out of the nucleus and trigger cell death in susceptible cells.
Half-life: Human half-life is unknown. No human pharmacokinetic study was found.
Related to FOXO4-DRI
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Humanin: A peptide the body makes; injection benefits and safety remain unproven.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Access an unapproved therapeutic good (health practitioners), Therapeutic Goods Administration
- Pulmonary hypertension, NHS
- Supply unlicensed medicinal products (specials), MHRA · MHRA
- Unapproved Drugs, FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.